Drug
Abbv 932
Abbv 932: highest development phase Phase 1, developed by AbbVie. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABBV-932 NCT07024797 | Phase 1 | Healthy Volunteer |
| ABBV-932 NCT05738850 | Phase 1 | Generalized Anxiety Disorder (GAD) |
Latest
No recent events.
Follow Abbv 932 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.